US Zulassung + Partnerschaft in 2010 = TOP PICK

Diese Aktie gehört wohl zu den günstigsten Biotechs überhaupt aber am besten macht eure Hausaufgaben selbst und ihr werdet staunen .

Hier hat man die Chance wirklich sehr gutes geld zu verdienen .


IntelliPharmaceutics (IPCI)

Marktkap: 17 Mio$
Cash: 8 Mio$
Kurs: 1,50 $

Shares Out: 10,9 M


Pipeline
www.intellipharmaceutics.com/pipeline.cfm


Präsentation März 2010
files.shareholder.com/downloads/...b7/Intellipharmaceutics.pdf


Intellipharmaceutics' development milestones for 2010 include the following:

-- Potential conclusion of the ongoing litigation process and/or FDA
approval of Focalin XR

-- File and have accepted for review by the FDA, two additional ANDA applications

-- Establish at least one additional development/marketing alliance

-- Complete successful manufacturing of clinical batches of Rexista(TM)

-- Complete Phase 1 studies using clinical batches of Rexista(TM)

-- Schedule a pre-IND meeting with FDA to discuss Rexista(TM) clinical
development plan

Die News bedeutet das der Weg für die Zulassung frei ist .. Meine Empfehlung lautet alles unter 2$ wegkaufen denn IPCI ist mit 17 Mio$ Marktkapitalisierung gnadenlos unterbewertet .
Viel Glück

Intellipharmaceutics Announces Settlement for its Generic Version of Focalin XR(R)

TORONTO, March 11, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. ( Nasdaq :IPCI) (TSX:I) today announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey, and Elan Pharma International Ltd. has settled its patent suit in the U.S. District Court for the District of Delaware, with Intellipharmaceutics Corp., a wholly-owned subsidiary of Intellipharmaceutics International, and its licensee Par Pharmaceutical, Inc. over a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR® (dexmethylphenidate hydrochloride). The terms of the settlements are confidential and remain subject to regulatory and court approval.

Verpasst die gelegenheit des Jahres nicht ...Die Aktie kann dieses Jahr noch über 10$ steigen .

Es bleibt natürlich eure Entscheidung .

Marktkap ist immer noch ein Witz mit rund  22 Mio$...

ih.advfn.com/...hart&s=N%5EIPCI&p=0&t=19&vol=1

Und ist nach wie vor gnadenlos unterbewertet
ih.advfn.com/...hart&s=N%5EIPCI&p=0&t=19&vol=1

Geillllllllllllllllllllllllllllllll

www.tradingmarkets.com/news/stock-alert/...celgene-842977.html

100-200% sind immer locker möglich ...

IntelliPharmaceutics (IPCI)

Marktkap: 44 Mio$
Cash: 8 Mio$
Kurs: 4,14 $

Shares Out: 10,9 M     ( CEO hält 6 Mio Aktien )


Präsentation März 2010
files.shareholder.com/downloads/...b7/Intellipharmaceutics.pdf


Pipeline
www.intellipharmaceutics.com/pipeline.cfm



CEO hält 6 Million Aktien ...
secfilings.nasdaq.com/...D&RcvdDate=11%2F2%2F2009&pdf=



Intellipharmaceutics' development milestones for 2010 include the following:

-- Potential conclusion of the ongoing litigation process and/or FDA
approval of Focalin XR

-- File and have accepted for review by the FDA, two additional ANDA applications

-- Establish at least one additional development/marketing alliance

-- Complete successful manufacturing of clinical batches of Rexista(TM)

-- Complete Phase 1 studies using clinical batches of Rexista(TM)

-- Schedule a pre-IND meeting with FDA to discuss Rexista(TM) clinical
development plan



Par Pharma (PRX) ist Zweitgrößter Aktionär ...

IPC's shareholders are expected to own approximately 86% of the outstanding common shares of the combined company and Vasogen's shareholders are expected to own approximately 14% of the outstanding common shares. IPC and Vasogen are currently assessing the appropriate capital structure for the combined company moving forward, which will take into consideration of a number of factors, including input from discussions with NASDAQ and the TSX. Following this assessment, IPC and Vasogen plan to outline their proposal and plans in a joint proxy circular to be provided to shareholders, which is expected to be filed in the coming weeks. Dr. Isa Odidi and Dr. Amina Odidi would together beneficially own approximately 55.3% of the combined company. IPC's second largest shareholder, Par Pharmaceutical, which acquired an equity interest in IPC in 2007 at the same time as it entered into a product commercialization agreement with IPC for the development and commercialization of four product candidates, would effectively own approximately 3.6% of the combined company after closing. The combined company will retain ownership of Vasogen's intellectual property; however, the development focus is expected to be principally on IPC's current product pipeline.

globenewswire.com/news-release/2015/05/26/...M-Technology.html

wann kommt die Zulassung?

Bald kommt die Zulassung!

Odidi Holdings Inc increased Position in IntelliPharmaCeutics International Inc. (TSE:I)

Odidi Holdings Inc has filled a SC 13D/A form regarding Intellipharmaceutics International Inc  4.45 -0.02 -0.45%. Filing Link: 000117184315003373. Per Odidi Holdings Inc’s filing, the filler reported increased stake in the company by 6.85% to 8,789,676 shares. Odidi Holdings Inc now owns 33.1% of the company. This form was required due to trading activity on May 29, 2015.



Why Odidi Holdings Inc Holds IntelliPharmaCeutics International Inc. (TSE:I)




Purpose of Transaction

.


The purpose of the dispositions of the Common Shares reported in Item 5(c) below were to allow Holdings to satisfy certain cash requirements. The shares acquired as reported in Item 5(c) below were acquired by the Reporting Persons for investment purposes.


Form 13D is SEC filing that must be submitted within 10 days, by anyone who acquires beneficial ownership of more than 5% of any publicly traded securities. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing. These filings may be a precursor to hostile takeovers, company breakups, and other “change of control” events.


Read more: www.octafinance.com/...odidi-holdings-inc/74275/#ixzz3cgAMBm8d

Can Intellipharmaceutics International Inc. (NASDAQ:IPCI) Keep Up with Analyst Expectations?

on June 30, 2015  
www.investornewswire.com/analyst-views/...-expectations/17276/  

Monster News!

the United States Food and Drug Administration ("FDA") has indicated to the Company that it has rescinded its previous requirement that the Company meet newly-imposed conditions for bioequivalence prior to receiving final approval for the Company’s tentatively-approved strengths of its generic Focalin XR® (dexmethylphenidate hydrochloride extended-release) capsules (the “Product”). The strengths affected include 5 mg, 10 mg, 20 mg and 40 mg. The already-approved 15 mg and 30 mg strengths now in the market are not affected.

Bald die 4$ Marke!!!

interessant... +50% sollten drinn sein oder, m.M.

​

prima... $$$